Royalty Pharma plc EVP Marshall Urist filed a Form 4 on November 6, 2026, disclosing two transactions dated November 4 and November 6, 2026, involving the acquisition of Class A Ordinary Shares and an exchange of limited partnership interests in RPI US Partners 2019, LP.

Key Highlights

  • Exempt share acquisition: On November 4, 2026, Urist acquired 5,341 Class A Ordinary Shares at $0 in connection with the settlement of Equity Performance Awards, held directly.
  • LP interest exchange: On November 6, 2026, 15,000 limited partnership interests in RPI US Partners 2019, LP were exchanged (transaction code C) for 150,000 Class A Ordinary Shares, held indirectly by Sandy Lamm LLC.
  • Post-transaction direct holdings: Following the November 4 transaction, Urist directly holds 5,341 Class A Ordinary Shares.
  • Indirect holdings: Following reported transactions, Urist indirectly holds 150,000 Class A Ordinary Shares through Sandy Lamm LLC and 19,020 Class A Ordinary Shares through an IRA.
  • Remaining derivative position: Following reported transactions, 229,412 LP interests in RPI US Partners 2019, LP are beneficially owned indirectly through Sandy Lamm LLC.
  • Additional holding noted: The filing states Urist holds Class E Ordinary Shares of Royalty Pharma Holdings Limited exchangeable into 1,356,528 Class A Ordinary Shares, subject to vesting conditions.

Urist's November 2026 Transactions at Royalty Pharma

According to the filing, Marshall Urist, Executive Vice President of Research and Investments at Royalty Pharma plc (NASDAQ:RPRX), reported two distinct transactions. On November 4, 2026, he acquired 5,341 Class A Ordinary Shares directly at a price of $0, described in the filing as "the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."

On November 6, 2026, the filing reports a conversion transaction (code C) in which 15,000 limited partnership interests in RPI US Partners 2019, LP held indirectly through Sandy Lamm LLC were exchanged for 150,000 Class A Ordinary Shares, also held indirectly through Sandy Lamm LLC, at $0 price. The filing explains that each RPI US LP interest is exchanged for ten Class B Interests in Royalty Pharma Holdings Limited, and each Class B Interest is then exchanged for one Class A Ordinary Share, all pursuant to the Amended and Restated Exchange Agreement with no additional value paid by the reporting person.

In addition to the directly and indirectly held Class A Ordinary Shares disclosed in the transaction tables, the filing notes that Urist indirectly holds 19,020 Class A Ordinary Shares through an IRA. The filing also discloses that Urist holds Class E Ordinary Shares of Royalty Pharma Holdings Limited exchangeable into 1,356,528 Class A Ordinary Shares, with those Class E shares described as subject to vesting conditions. The form was signed by Sean Weisberg as Attorney-in-Fact for Marshall Urist on November 6, 2026.

What Was Disclosed

Royalty Pharma EVP Marshall Urist disclosed the acquisition of 5,341 Class A Ordinary Shares via Equity Performance Award settlement and the exchange of 15,000 LP interests for 150,000 Class A Ordinary Shares, with post-transaction beneficial ownership detailed across direct and indirect accounts.